WO2022079664 - BENZALKONIUM CHLORIDE FOR USE IN TREATING CONJUNCTIVITIS AND/OR COVID-19
National phase entry:
Publication Number
WO/2022/079664
Publication Date
21.04.2022
International Application No.
PCT/IB2021/059468
International Filing Date
14.10.2021
Title **
[English]
BENZALKONIUM CHLORIDE FOR USE IN TREATING CONJUNCTIVITIS AND/OR COVID-19
[French]
CHLORURE DE BENZALKONIUM POUR UNE UTILISATION DANS LE TRAITEMENT DE LA CONJONCTIVITE ET/OU DE LA COVID-19
Applicants **
BAUSCH & LOMB IRELAND LIMITED
3013 Lake Drive
Citywest Business Park
Dublin, IE
Inventors
MCCORMICK, Patrick
1400 N. Goodman Street
Rochester, New York 14609, US
MILLARD, Kimberly
1400 N. Goodman Street
Rochester, New York 14609, US
Priority Data
63/092,399
15.10.2020
US
63/183,928
04.05.2021
US
63/226,614
28.07.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3218 | |
| EPO | Filing, Examination | 37253 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 640 | |
| USA | Filing, Examination | 16110 |
Total: 57812 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Methods for treating coronavirus disease 2019 (COVID-19), including at least one ocular manifestation of COVID-19, methods for treating conjunctivitis, and methods for reducing COVID-19 transmission comprising administering an effective amount of benzalkonium chloride are disclosed. Pharmaceutical compositions comprising benzalkonium chloride are also disclosed.[French]
L'invention concerne des procédés de traitement de la maladie à coronavirus 2019 (COVID-19), comprenant au moins une manifestation oculaire de COVID-19, des procédés de traitement de conjonctivite, et des procédés de réduction de la transmission de COVID-19 comprenant l'administration d'une quantité efficace de chlorure de benzalkonium. L'invention concerne également des compositions pharmaceutiques comprenant du chlorure de benzalkonium.